Cancer liquid biopsies by Oxford Nanopore Technologies sequencing of cell-free DNA: from basic research to clinical applications

Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer 2024-11, Vol.23 (1), p.265-15
Main Authors: Si, Hua-Qi, Wang, Peng, Long, Fei, Zhong, Wei, Meng, Yuan-Dong, Rong, Yuan, Meng, Xiang-Yu, Wang, Fu-Bing
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Tumor - analysis
Biomarkers, Tumor - genetics
Cancer
Care and treatment
Cell-free DNA
Circulating Tumor DNA - analysis
Circulating Tumor DNA - genetics
Diagnosis
DNA
Genetic aspects
High-Throughput Nucleotide Sequencing - methods
Humans
Liquid biopsies
Liquid Biopsy - methods
Nanopore Sequencing - methods
Nanopores
Neoplasms - blood
Neoplasms - diagnosis
Neoplasms - genetics
Neoplasms - pathology
Oncology
Oxford Nanopore Technologies
Patient compliance
Personalized medicine
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liquid biopsies, in particular, analysis of cell-free DNA, are expected to revolutionize the current landscape of cancer diagnostics and treatment. However, the existing methods for cfDNA-based liquid biopsies for cancer have certain limitations, such as fragment interruption and GC bias, which are likely to be resolved by the emerging Oxford Nanopore Technologies (ONT), characterized by long read-length, fast read-times, high throughput, and polymerase chain reaction-free. In this review, we summarized the current literatures regarding the feasibility and applications of cfDNA-based liquid biopsies using ONT for cancer management, a possible game-changer that we believe is promising in detecting multimodal biomarkers and can be applied in a wide range of oncology utilities including early screening, diagnosis, and treatment monitoring.
ISSN:1476-4598
1476-4598
DOI:10.1186/s12943-024-02178-6